
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.
Here’s a look back at notable news between July and September 2025.
The third quarter of 2025 saw a flurry of activity in the urologic oncology space. Bladder cancer continues to generate substantial buzz, particularly with the September FDA approvals of gemcitabine intravesical system (Inlexzo; formerly TAR-200) in BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors and pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; Merck) for subcutaneous injection across all previously approved solid tumor indications of IV pembrolizumab in adults and adolescents (≥12 years).




